Skip to main content

Advertisement

SpringerLink
Log in

Pentraxin 3, a serum biomarker in human T-cell lymphotropic virus type-1-associated myelopathy patients and asymptomatic carriers

  • Original Investigation
  • Published:
Medical Microbiology and Immunology Aims and scope Submit manuscript

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1) can induce a neuroinflammatory condition that leads to myelopathy. Pentraxin 3 (PTX3) is an acute-phase protein that its plasma concentration increases during inflammation. We aimed to determine whether PTX3 serum level is elevated in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients and HTLV-1 asymptomatic carriers (ACs) and evaluate its association with proviral load and clinical features. The serum level of PTX3 was measured using an enzyme-linked immunosorbent assay in 30 HAM patients, 30 HTLV-1 ACs, and 30 healthy controls. Also, the HTLV-1 proviral load was determined via real-time PCR technique. The findings showed that PTX3 serum level was significantly higher in HAM patients than in both asymptomatic carriers and healthy controls (p values < 0.0001). No correlation between PTX3 and the proviral load was observed in HAM patients and asymptomatic carriers (r = − 0.238, p = 0.205 and r = − 0.078, p = 0.681, respectively). The findings showed that there was no significant correlation between PTX3 and motor disability grading (MDG) (r = − 0.155, p = 0.41) nor urinary disturbance score (UDS) (r = − 0.238, p = 0.20). Higher levels of PTX3 are associated with HTLV-1-associated myelopathy compared to asymptomatic carriers. This finding may support the idea that PTX3 has the potential as a diagnostic biomarker.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability statement

The data generated or analyzed during this study are available from corresponding author on reasonable request.

References

  1. Gessain A, Cassar O (2012) Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 15(3):388. https://doi.org/10.3389/fmicb.2012.00388

    Article  Google Scholar 

  2. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, Sohgandi L, Azarpazhooh MR, Rezaee SA, Farid R, Bazarbachi A (2011) High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol 52(3):172–176. https://doi.org/10.1016/j.jcv.2011.07.004

    Article  PubMed  Google Scholar 

  3. Nozuma S, Kubota R, Jacobson S (2020) Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis. J Neurovirol 26(5):652–663. https://doi.org/10.1007/s13365-020-00881-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mohammadi A, Fazeli B, Poursina Z, Tehranian F, Vakili V, Boostani R, Rafatpanah H (2019) HTLV-1-infected asymptomatic carriers compared to HAM/TSP patients over-express the apoptosis- and cytotoxicity-related molecules. Med Microbiol Immunol 208(6):835–844. https://doi.org/10.1007/s00430-019-00625-6

    Article  PubMed  Google Scholar 

  5. Gudo ES, Silva-Barbosa SD, Linhares-Lacerda L, Ribeiro-Alves M, Real SC, Bou-Habib DC, Savino W (2015) HAM/TSP-derived HTLV-1-infected T cell lines promote morphological and functional changes in human astrocytes cell lines: possible role in the enhanced T cells recruitment into central nervous system. Virol J 12(12):165. https://doi.org/10.1186/s12985-015-0398-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Freitas NL, Gomes YCP, Souza FDS, Torres RC, Echevarria-Lima J, Leite ACCB, Lima MASD, Araújo AQC, Silva MTT, Espíndola OM (2022) Lessons from the cerebrospinal fluid analysis of HTLV-1-infected individuals: biomarkers of inflammation for HAM/TSP development. Viruses 14(10):2146. https://doi.org/10.3390/v14102146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lopes Martins AL, Rios Grassi MF, de Aquino FA, Lacerda Araujo JP, Paixao TS, Galvão-Castro B, Boa-Sorte N (2018) Human T-lymphotropic virus-1-associated myelopathy/tropical spastic paraparesis is associated with sexual dysfunction in infected women of reproductive age. Sex Med 6(4):324–331. https://doi.org/10.1016/j.esxm.2018.07.002. (Epub 2018 Sep 1)

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hatatian N, Bosstani R, Mohammadi A, Mehraban S, Mahdifar M, Zemorshidi F, Mozhgani SH, Haji Ghadimi A, Foroughipour M, Rafatpanah H (2021) Evaluation of interleukin-32 and cyclooxygenase-2 expression in HAM/TSP patients and HTLV-1 asymptomatic carriers. Iran J Basic Med Sci 24(7):992–996. https://doi.org/10.22038/ijbms.2021.50821.11569

    Article  PubMed  PubMed Central  Google Scholar 

  9. Guerra M, Luna T, Souza A, Amorim C, Carvalho NB, Carvalho L, Tanajura D, Cardoso LS, Carvalho EM, Santos S (2018) Local and systemic production of proinflammatory chemokines in the pathogenesis of HAM/TSP. Cell Immunol 334:70–77. https://doi.org/10.1016/j.cellimm.2018.09.009

    Article  CAS  PubMed  Google Scholar 

  10. Souza FDS, Freitas NL, Gomes YCP, Torres RC, Echevarria-Lima J, da Silva-Filho IL, Leite ACCB, de Lima MASD, da Silva MTT, Araújo AQC, Espíndola OM. Following the clues: usefulness of biomarkers of neuroinflammation and neurodegeneration in the investigation of HTLV-1-associated myelopathy progression. Front Immunol. 2021;12:737941. https://doi.org/10.3389/fimmu.2021.737941

  11. Yi L, Tang J, Shi C, Zhang T, Li J, Guo F, Zhang W (2020) Pentraxin 3, TNF-α, and LDL-C are associated with carotid artery stenosis in patients with ischemic stroke. Front Neurol 10(10):1365. https://doi.org/10.3389/fneur.2019.01365

    Article  PubMed  PubMed Central  Google Scholar 

  12. Qi S, Zhao F, Li Z, Liang F, Yu S (2020) Silencing of PTX3 alleviates LPS-induced inflammatory pain by regulating TLR4/NF-κB signaling pathway in mice. Biosci Rep 40(2):BSR20194208. https://doi.org/10.1042/BSR20194208

  13. Ummenthum K, Peferoen LA, Finardi A, Baker D, Pryce G, Mantovani A, Bsibsi M, Bottazzi B, Peferoen-Baert R, van der Valk P, Garlanda C, Kipp M, Furlan R, van Noort JM, Amor S (2016) Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease. Eur J Immunol 46(3):701–711. https://doi.org/10.1002/eji.201545950

    Article  CAS  PubMed  Google Scholar 

  14. Moalli F, Paroni M, Véliz Rodriguez T, Riva F, Polentarutti N, Bottazzi B, Valentino S, Mantero S, Nebuloni M, Mantovani A, Bragonzi A, Garlanda C (2011) The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa. J Immunol 186(9):5425–5434. https://doi.org/10.4049/jimmunol.1002035

    Article  CAS  PubMed  Google Scholar 

  15. Rodriguez-Grande B, Varghese L, Molina-Holgado F, Rajkovic O, Garlanda C, Denes A, Pinteaux E (2015) Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia. J Neuroinflamm 24(12):15. https://doi.org/10.1186/s12974-014-0227-y

    Article  CAS  Google Scholar 

  16. Polentarutti N, Bottazzi B, Di Santo E, Blasi E, Agnello D, Ghezzi P, Introna M, Bartfai T, Richards G, Mantovani A (2000) Inducible expression of the long pentraxin PTX3 in the central nervous system. J Neuroimmunol 106(1–2):87–94. https://doi.org/10.1016/s0165-5728(00)00214-9

    Article  CAS  PubMed  Google Scholar 

  17. Ravizza T, Moneta D, Bottazzi B, Peri G, Garlanda C, Hirsch E, Richards GJ, Mantovani A, Vezzani A (2001) Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. Neuroscience 105(1):43–53. https://doi.org/10.1016/s0306-4522(01)00177-4

    Article  CAS  PubMed  Google Scholar 

  18. Lee HW, Choi J, Suk K (2011) Increases of pentraxin 3 plasma levels in patients with Parkinson’s disease. Mov Disord 26(13):2364–2370. https://doi.org/10.1002/mds.23871

    Article  PubMed  Google Scholar 

  19. Bourgeois MA, Denslow ND, Seino KS, Barber DS, Long MT (2011) Gene expression analysis in the thalamus and cerebrum of horses experimentally infected with West Nile virus. PLoS ONE 6(10):e24371. https://doi.org/10.1371/journal.pone.0024371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zatta M, Di Bella S, Bottazzi B, Rossi F, D’Agaro P, Segat L, Fabbiani M, Mantovani A, Luzzati R (2020) Determination of pentraxin 3 levels in cerebrospinal fluid during central nervous system infections. Eur J Clin Microbiol Infect Dis 39(4):665–670. https://doi.org/10.1007/s10096-019-03767-w

    Article  CAS  PubMed  Google Scholar 

  21. Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, Bittner C, Fialka-Moser V (2008) Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med 40(8):665–671. https://doi.org/10.2340/16501977-0235

    Article  PubMed  Google Scholar 

  22. Charalambous CP (2014) Interrater reliability of a modified Ashworth scale of muscle spasticity. Classic papers in orthopaedics. Springer, Berlin, pp 415–417

  23. Izumo S, Usuku K, Osame M, Arimura K, Igata A (1988) Effect of alpha-interferon treatment on HTLV-I associated myelopathy (HAM). Neurology 39(Suppl 1):242

    Google Scholar 

  24. Ramezani S, Shirdel A, Rafatpanah H, Akbarin MM, Tarokhian H, Rahimi H, Bari A, Jahantigh HR, Rezaee SA (2017) Assessment of HTLV-1 proviral load, LAT, BIM, c-FOS and RAD51 gene expression in adult T cell leukemia/lymphoma. Med Microbiol Immunol 206(4):327–335. https://doi.org/10.1007/s00430-017-0506-1

    Article  CAS  PubMed  Google Scholar 

  25. Staubli SM, Schäfer J, Rosenthal R, Zeindler J, Oertli D, Nebiker CA (2019) The role of CRP and Pentraxin 3 in the prediction of systemic inflammatory response syndrome and death in acute pancreatitis. Sci Rep 9(1):18340. https://doi.org/10.1038/s41598-019-54910-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Shoeibi A, Rafatpanah H, Azarpazhooh A, Mokhber N, Hedayati-Moghaddam MR, Amiri A, Hashemi P, Foroghipour M, Hoseini RF, Bazarbachi A, Azarpazhooh MR (2013) Clinical features of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in northeast Iran. Acta Neurol Belg 113(4):427–433. https://doi.org/10.1007/s13760-013-0194-6

    Article  PubMed  Google Scholar 

  27. Bozza S, Bistoni F, Gaziano R, Pitzurra L, Zelante T, Bonifazi P, Perruccio K, Bellocchio S, Neri M, Iorio AM, Salvatori G, De Santis R, Calvitti M, Doni A, Garlanda C, Mantovani A, Romani L (2006) Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 108(10):3387–3396. https://doi.org/10.1182/blood-2006-03-009266

    Article  CAS  PubMed  Google Scholar 

  28. Porte R, Davoudian S, Asgari F, Parente R, Mantovani A, Garlanda C, Bottazzi B (2019) The long pentraxin PTX3 as a humoral innate immunity functional player and biomarker of infections and sepsis. Front Immunol 12(10):794. https://doi.org/10.3389/fimmu.2019.00794

    Article  CAS  Google Scholar 

  29. Vengen IT, Enger TB, Videm V, Garred P (2017) Pentraxin 3, ficolin-2 and lectin pathway associated serine protease MASP-3 as early predictors of myocardial infarction—the HUNT2 study. Sci Rep 20(7):43045. https://doi.org/10.1038/srep43045

    Article  CAS  Google Scholar 

  30. Oggioni M, Mercurio D, Minuta D, Fumagalli S, Popiolek-Barczyk K, Sironi M, Ciechanowska A, Ippati S, De Blasio D, Perego C, Mika J, Garlanda C, De Simoni MG (2021) Long pentraxin PTX3 is upregulated systemically and centrally after experimental neurotrauma, but its depletion leaves unaltered sensorimotor deficits or histopathology. Sci Rep 11(1):9616. https://doi.org/10.1038/s41598-021-89032-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wang H, Wang K, Wang C, Zhong X, Qiu W, Hu X (2013) Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 19(7):926–931. https://doi.org/10.1177/1352458512457845

    Article  CAS  PubMed  Google Scholar 

  32. Ryu WS, Kim CK, Kim BJ, Kim C, Lee SH, Yoon BW (2012) Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. Atherosclerosis 220(2):581–586. https://doi.org/10.1016/j.atherosclerosis.2011.11.036

    Article  CAS  PubMed  Google Scholar 

  33. Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, Cuccovillo I, Cugno M, Iapichino G, Gattinoni L, Pesenti A, Mantovani A (2010) Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med 36(4):621–629. https://doi.org/10.1007/s00134-010-1752-5

    Article  CAS  PubMed  Google Scholar 

  34. Ciancarella V, Lembo-Fazio L, Paciello I, Bruno AK, Jaillon S, Berardi S, Barbagallo M, Meron-Sudai S, Cohen D, Molinaro A, Rossi G, Garlanda C, Bernardini ML (2018) Role of a fluid-phase PRR in fighting an intracellular pathogen: PTX3 in Shigella infection. PLoS Pathog 14(12):e1007469. https://doi.org/10.1371/journal.ppat.1007469

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, Benagiano M, D’Elios MM, Mantovani A, Del Prete G (2005) IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 7(1):1–8. https://doi.org/10.1016/j.micinf.2004.09.004

    Article  CAS  PubMed  Google Scholar 

  36. Wagenaar JF, Goris MG, Gasem MH, Isbandrio B, Moalli F, Mantovani A, Boer KR, Hartskeerl RA, Garlanda C, van Gorp EC (2009) Long pentraxin PTX3 is associated with mortality and disease severity in severe Leptospirosis. J Infect 58(6):425–432. https://doi.org/10.1016/j.jinf.2009.04.004

    Article  PubMed  Google Scholar 

  37. Sprong T, Peri G, Neeleman C, Mantovani A, Signorini S, van der Meer JW, van Deuren M (2009) Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock 31(1):28–32. https://doi.org/10.1097/SHK.0b013e31817fd543

    Article  CAS  PubMed  Google Scholar 

  38. Mairuhu AT, Peri G, Setiati TE, Hack CE, Koraka P, Soemantri A, Osterhaus AD, Brandjes DP, van der Meer JW, Mantovani A, van Gorp EC (2005) Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J Med Virol 76(4):547–552. https://doi.org/10.1002/jmv.20397

    Article  CAS  PubMed  Google Scholar 

  39. Kim HS, Won S, Lee EK, Chun YH, Yoon JS, Kim HH, Kim JT (2016) Pentraxin 3 as a clinical marker in children with lower respiratory tract infection. Pediatr Pulmonol 51(1):42–48. https://doi.org/10.1002/ppul.23199

    Article  PubMed  Google Scholar 

  40. Biagi E, Col M, Migliavacca M, Dell’Oro M, Silvestri D, Montanelli A, Peri G, Mantovani A, Biondi A, Rossi MR (2008) PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. J Pediatr Hematol Oncol 30(12):881–885. https://doi.org/10.1097/MPH.0b013e318180bc1d

    Article  PubMed  Google Scholar 

  41. Kao SJ, Yang HW, Tsao SM, Cheng CW, Bien MY, Yu MC, Bai KJ, Yang SF, Chien MH (2013) Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia. Clin Chem Lab Med 51(4):907–913. https://doi.org/10.1515/cclm-2012-0459

    Article  CAS  PubMed  Google Scholar 

  42. Jaillon S, Moalli F, Ragnarsdottir B, Bonavita E, Puthia M, Riva F, Barbati E, Nebuloni M, Cvetko Krajinovic L, Markotic A, Valentino S, Doni A, Tartari S, Graziani G, Montanelli A, Delneste Y, Svanborg C, Garlanda C, Mantovani A (2014) The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. Immunity 40(4):621–632. https://doi.org/10.1016/j.immuni.2014.02.015

    Article  CAS  PubMed  Google Scholar 

  43. Vakili R, Sabet F, Aahmadi S, Boostani R, Rafatpanah H, Shamsian A, Rezaee SA (2013) Human T-lymphotropic Virus Type I (HTLV-I) proviral load and clinical features in Iranian HAM/TSP patients: comparison of HTLV-I proviral load in HAM/TSP patients. Iran J Basic Med Sci 16(3):268–272

    PubMed  PubMed Central  Google Scholar 

  44. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, Bunce M, Ogg GS, Welsh KI, Weber JN, Lloyd AL, Nowak MA, Nagai M, Kodama D, Izumo S, Osame M, Bangham CR (1999) HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 96(7):3848–3853. https://doi.org/10.1073/pnas.96.7.3848

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Reading PC, Bozza S, Gilbertson B, Tate M, Moretti S, Job ER, Crouch EC, Brooks AG, Brown LE, Bottazzi B, Romani L, Mantovani A (2008) Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol 180(5):3391–3398. https://doi.org/10.4049/jimmunol.180.5.3391

    Article  CAS  PubMed  Google Scholar 

  46. Foo SS, Chen W, Taylor A, Sheng KC, Yu X, Teng TS, Reading PC, Blanchard H, Garlanda C, Mantovani A, Ng LF, Herrero LJ, Mahalingam S (2015) Role of pentraxin 3 in shaping arthritogenic alphaviral disease: from enhanced viral replication to immunomodulation. PLoS Pathog. 11(2):e1004649. https://doi.org/10.1371/journal.ppat.1004649. (Erratum in: PLoS Pathog. 2015 Apr;11(4):e1004797)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was performed as the thesis for neurology specialty degree of the first author. The authors should appreciate the support of Vice-chancellor for research at Mashhad University of Medical Sciences (990557).

Funding

No funding was obtained for this study.

Author information

Authors and Affiliations

  1. Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran

    Motahareh Manzarinejad, Reza Boostani & Fariba Zemorshidi

  2. Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Zohreh Vahidi

  3. Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Majid Khadem-Rezaiyan

  4. Rheumatic Disease Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Houshang Rafatpanah

Authors
  1. Motahareh Manzarinejad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zohreh Vahidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reza Boostani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Majid Khadem-Rezaiyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Houshang Rafatpanah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fariba Zemorshidi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MM, ZV, HR and FZ performed research; MKR Analyzed data; ZV and FZ conceived and designed research; RB supervised and coordinated the study; MM wrote the paper draft; FZ contributed to manuscript editing. The manuscript was approved by all the authors.

Corresponding author

Correspondence to Fariba Zemorshidi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and consent to participate

The study protocol was approved by the ethics committee of Mashhad University of Medical Sciences with approval code IR.MUMS.MEDICAL.REC.1399.44.7. All the participants were informed about the study procedure and provided written consent before they participated in the study.

Additional information

Edited by Matthias J. Reddehase.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Manzarinejad, M., Vahidi, Z., Boostani, R. et al. Pentraxin 3, a serum biomarker in human T-cell lymphotropic virus type-1-associated myelopathy patients and asymptomatic carriers. Med Microbiol Immunol 212, 271–278 (2023). https://doi.org/10.1007/s00430-023-00770-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00430-023-00770-z

Keywords

Search

Navigation